Evogene and BASF Sign Multi-Year Collaboration Deal to Develop Novel Insecticides

Evogene (EVGN), a biotechnology company developing novel products for life science markets, said Tuesday that it has entered into a new collaboration with chemical company BASF to develop novel insecticides based on new binding areas (Site-of-Action or SoA) on key insecticidal target proteins.

EVGN shares rose more than 5% in the pre-market session.

The companies also announced that the collaboration achieved its first project milestone, with the joint nomination of a set of novel SoAs, discovered by Evogene that will advance to the discovery phase of relevant bioactive compounds.

In the initial phase of the collaboration, Evogene developed a smart process to identify potential novel compounds that act on new proteins and binding sites.

In the next phase of this collaboration, Evogene will utilize its Computational Predictive Biology (CPB) platform for the discovery of the relevant chemistry to address the new SoAs. Compounds discovered by Evogene will then enter BASF’s insecticide discovery platform for insect efficacy screening and testing to determine the chemistry’s ability to modulate the respective target proteins.

The financial terms of the collaboration have not been disclosed.

Leave a Reply

Your email address will not be published. Required fields are marked *